Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brenetafusp in Advanced PRAME-Positive Cancers
NCT04262466Phase 2Active, not recruiting
- Sponsor
- Immunocore
- Start
- Feb 2020
- Primary completion
- Oct 2026
- Countries
- 17
01
Overview
Phase 2, open-label trial of brenetafusp in solid tumor (advanced stage) (5 arms), sponsored by Immunocore. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 30 days and 5 more. Started Feb 2020; status: active, not recruiting.
02
Drugs
brenetafusp
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04262466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262466.